Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

Patient with two prior lines of systemic treatment (chemotherapy, immunotherapy or association)
Other evolutive neoplasic disease
Severe hepatic insufficiency
Severe renal insufficiency
Somatic or psychiatric co-morbidity incompatible with the protocol
Leptomeningeal or cerebral metastatic dissemination
Pregnant or lactating woman
Other antitumoral treatment
Patient participating to another clinical trial with an experimental drug
Known hypersensitivity to Imatinib or one of its excipients
Resecable single metastasis

Imatinib in Adult Patients With Metastatic Ocular Melanoma